We report herein on the effects of a 12-week cycle of doxycycline administration on the circulating levels of the known targets MMP2, MMP9 and their inhibitor TIMP2 in breast cancer patients with bone metastases and their further associations with relevant clinical outcomes. Here, TIMP2 is linked to breast cancer.